Comment by DrBenCarson
Comment by DrBenCarson a year ago
Would rather have Mounjaro and Zepbound
Comment by DrBenCarson a year ago
Would rather have Mounjaro and Zepbound
The cynic in me thinks they are only going for Semaglutide because the patent expires in several places in 2026, tirzepatide has another ten years.
The patent on the manufacturing process, not the peptide itself.
Or do both, and let them compete with each other for Medicare's business.
Cheap drugs have massive downward price pressure on alternatives.